Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Otsuka Pharmaceutical
Biotech
Why other Big Pharmas could follow Lilly into psychedelics
Industry experts told Fierce that Eli Lilly's $2.8 billion acquisition of AtaiBeckley should give the psychedelics space added momentum.
Will Maddox
,
Darren Incorvaia
Jul 20, 2026 4:00am
Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog
Mar 27, 2026 11:00am
Otsuka pens $420M deal for Asia rights to 4DMT gene therapy
Oct 31, 2025 5:09am
Otsuka inks $613M deal for Swedish biotech's IL1RAP antibodies
Jul 16, 2025 1:37pm
UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss
Jul 8, 2025 10:17am
Otsuka's $670M pact to point Harbour's TCE to autoimmune disease
Jun 23, 2025 6:29am